Risk of MACE Similar With Degarelix and Leuprolide in Prostate Cancer
Renal & Urology News,
Degarelix did not reduce the risk of major adverse cardiovascular events (MACE) when compared with leuprolide in patients with…
Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, ...
End Points,
Zachary Brennan Senior Editor One of the major reasons the FDA’s accelerated approval pathway receives so many accolades and so…
Risk of MACE Similar With Degarelix and Leuprolide in Prostate Cancer
Cancer Therapy Advisor,
Degarelix did not reduce the risk of major adverse cardiovascular events (MACE) when compared with leuprolide in patients with…